You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Nelfinavir mesylate
Nelfinavir mesylate is an orally active human immunodeficiency virus protease inhibitor. Potently inhibits HIV-1 protease (Ki = 2 nM) in vitro. Also exhibits anti-MERS-CoV activity in Vero cells in vitro (IC50 = 0.08 μM).
Sold for research purposes under agreement from Pfizer Inc.
Technical Data for Nelfinavir mesylate
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Nelfinavir mesylate
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Nelfinavir mesylate
The following data is based on the product molecular weight 663.89. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.51 mL||7.53 mL||15.06 mL|
|5 mM||0.3 mL||1.51 mL||3.01 mL|
|10 mM||0.15 mL||0.75 mL||1.51 mL|
|50 mM||0.03 mL||0.15 mL||0.3 mL|
Product Datasheets for Nelfinavir mesylate
References for Nelfinavir mesylate
References are publications that support the biological activity of the product.
Shetty et al (1996) Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob.Agents Chemother. 40 110 PMID: 8787890
Patick et al (1996) Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob.Agents Chemother. 40 29 PMID: 8787874
Gills et al (2007) Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy and apoptosis in vitro and in vivo. Clin.Cancer Res. 13 5183
Musarrat et al (2020) The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J.Med.Virol. 92 2087 PMID: 32374457
Ko et al (2021) Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. Viruses 13 PMID: 33918958
If you know of a relevant reference for Nelfinavir mesylate, please let us know.
View Related Products by Product Action
Keywords: Nelfinavir mesylate, Nelfinavir mesylate supplier, Orally, active, human, immunodeficiency, virus, proteases, inhibitors, Potent, inhibits, HIV-1, HIV1, HIV, AG1341, AG, 1341, Pfizer, COVID-19, MERS-CoV, middle, eastern, respiratory, coronavirus, Protease, Coronavirus, 3766, Tocris Bioscience
Citations for Nelfinavir mesylate
Citations are publications that use Tocris products.
Currently there are no citations for Nelfinavir mesylate. Do you know of a great paper that uses Nelfinavir mesylate from Tocris? Please let us know.
Reviews for Nelfinavir mesylate
There are currently no reviews for this product. Be the first to review Nelfinavir mesylate and earn rewards!
Have you used Nelfinavir mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.